53,839 Shares in Omnicell, Inc. $OMCL Purchased by Odyssean LLC

Key Points

• Odyssean LLC purchased 53,839 shares of Omnicell during the second quarter, valued at approximately $2.24 million, giving it a 0.12% stake. Institutional investors collectively own 97.70% of the company.
• Analyst sentiment remains broadly positive, with seven Buy ratings, one Hold, and one Sell; Omnicell has a “Moderate Buy” consensus rating and an average price target of $57.86, despite Wells Fargo lowering its target to $50.
• Omnicell beat quarterly earnings expectations, reporting $0.94 in EPS versus the $0.47 consensus and $312.21 million in revenue. Revenue rose 7.4% year over year, while the stock recently traded at $34.37.

Odyssean LLC purchased a new position in Omnicell, Inc. (NASDAQ:OMCL - Free Report) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 53,839 shares of the company's stock, valued at approximately $2,235,000. Odyssean LLC owned about 0.12% of Omnicell at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Raymond James Financial Inc. purchased a new position in shares of Omnicell during the 2nd quarter worth about $26,000. Versant Capital Management Inc grew its holdings in Omnicell by 38.7% in the second quarter. Versant Capital Management Inc now owns 1,053 shares of the company's stock valued at $44,000 after purchasing an additional 294 shares during the period. Clearstead Advisors LLC grew its holdings in Omnicell by 12,180.0% in the fourth quarter. Clearstead Advisors LLC now owns 1,228 shares of the company's stock valued at $56,000 after purchasing an additional 1,218 shares during the period. Kemnay Advisory Services Inc. acquired a new position in Omnicell during the fourth quarter worth approximately $58,000. Finally, Parkside Financial Bank & Trust increased its position in Omnicell by 1,708.1% during the fourth quarter. Parkside Financial Bank & Trust now owns 1,338 shares of the company's stock worth $61,000 after purchasing an additional 1,264 shares during the last quarter. Hedge funds and other institutional investors own 97.70% of the company's stock.

Analyst Ratings Changes

Several brokerages have recently issued reports on OMCL. Zacks Research cut shares of Omnicell from a "hold" rating to a "strong sell" rating in a research note on Friday, August 7th. Weiss Ratings raised Omnicell from a "hold (c-)" rating to a "hold (c)" rating in a research report on Tuesday, August 18th. Wall Street Zen upgraded Omnicell from a "buy" rating to a "strong-buy" rating in a report on Sunday, May 10th. KeyCorp reissued an "overweight" rating on shares of Omnicell in a research report on Monday, August 24th. Finally, Wells Fargo & Company cut their price objective on Omnicell from $55.00 to $50.00 and set an "overweight" rating on the stock in a report on Friday, July 31st. Seven research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $57.86.

Omnicell Price Performance

OMCL opened at $34.37 on Friday. Omnicell, Inc. has a 52-week low of $29.06 and a 52-week high of $55.00. The company has a 50 day moving average of $39.34 and a two-hundred day moving average of $39.24. The company has a market cap of $1.56 billion, a P/E ratio of 40.92, a P/E/G ratio of 0.87 and a beta of 0.97. The company has a quick ratio of 1.43, a current ratio of 1.64 and a debt-to-equity ratio of 0.13.

Omnicell (NASDAQ:OMCL - Get Free Report) last issued its earnings results on Thursday, July 30th. The company reported $0.94 EPS for the quarter, beating analysts' consensus estimates of $0.47 by $0.47. The business had revenue of $312.21 million for the quarter, compared to the consensus estimate of $310.21 million. Omnicell had a net margin of 3.13% and a return on equity of 5.66%. The business's revenue for the quarter was up 7.4% compared to the same quarter last year. During the same quarter last year, the firm posted $0.45 EPS. Omnicell has set its Q3 2026 guidance at 0.350-0.430 EPS and its FY 2026 guidance at 2.150-2.300 EPS. On average, analysts expect that Omnicell, Inc. will post 1.41 earnings per share for the current year.

About Omnicell

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company's offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell's analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.

Want to see what other hedge funds are holding OMCL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Omnicell, Inc. (NASDAQ:OMCL - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source